• Thumbnail

    Same difference

    With some of the world's biggest biologics teetering on the edge of the patent cliff, biosimilars are big business. Yet, with the market still in its infancy, it's not as easy as you might think to get these cheap biologics to the patients that need them

  • Thumbnail

    A rare discovery

    In rare diseases, the story of a drug's development is often an intensely personal one for the scientists, patient groups and, of course, patients. However, few of those personal stories have been made into a Hollywood movie. Meet John Crowley, chairman and CEO of rare disease company, Amicus Therapeutics

  • Thumbnail

    Patient-centricity: Ghost in the machine

    In the complex machine of modern healthcare, until recently the patient has been a small cog. In this special in-depth feature, we ask stakeholders from across healthcare to share their insights on how engaging patients is transforming the industry

  • Thumbnail

    Internal and external recognition and career development for marketers

    PharmaTimes Media invites marketers and teams to enter its prestigious Marketer of the Year competition, designed to benchmark talent within your organisation and across our industry.

  • Thumbnail

    Last chance to enter or nominate in Sales Manager of the Year

    With hundreds of nominations received so far, and two weeks still left until the closing date, the PharmaTimes Sales Representative of the Year is set be an exciting and highly representative competition.

News

View all
Thumbnail

Study data back efficacy of AZ novel antibiotic

A late-stage study has confirmed the efficacy of AstraZeneca's new combination antibiotic Zavicefta in patients with hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).

22nd July 2016

Thumbnail

US delay to Merck’s C.difficile antitoxin

Merck & Co's investigational clostridium difficile treatment has been hit with a setback in the US after regulators extended the review time for the drug by three months.

22nd July 2016

Thumbnail

Industry roundup – 21 July

Shire launches new paediatric indication for HyQvia; Stem cell therapies face commercial challenges; VBI moves forward with Zika Vaccine

21st July 2016

Thumbnail

Same difference

With some of the world's biggest biologics teetering on the edge of the patent cliff, biosimilars are big business. Yet, with the market still in its infancy, it's not as easy as you might think to get these cheap biologics to the patients that need them

Thumbnail

A shot in the arm

An ailing NHS needs an injection of innovation to survive. PharmaTimes speaks to the bright thinkers helping to transform the UK's health service

Thumbnail

SmartViews: Staying power

Building reputation is a long-term endeavour yet as pharma moves away from a traditional B2B model to embrace patients, it is becoming a crucial success factor

Thumbnail

SmartViews: Never say never

Pharmaceutical firms might reconsider any mergers or acquisitions that were initially ruled out as too challenging

Thumbnail

SmartViews: One small step

With moves towards greater transparency gaining momentum, pharma must do all it can to ensure patient safety

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download